The RNA analysis/transcriptomics market is projected to reach USD 8.7 billion by 2025 from USD 4.5 billion in 2020, at a CAGR of 13.9%

during the forecast period. The growth of this market is majorly driven by the increasing demand for personalized medicine, increasing pharmaceutical and biotechnology R&D expenditure and government funding for omics, and the increasing applications of RNA sequencing in the transcriptomics market.

New York, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "RNA Analysis/ Transcriptomics Market by Product, Technology, Application, End User, COVID-19 Impact - Global Forecast to 2025" - https://www.reportlinker.com/p05983737/?utm_source=GNW
The increasing focus on biomarker discovery and toxicogenomics, along with the increasing interest in outsourcing services, is expected to offer significant growth opportunities for the players operating in the global RNA analysis/transcriptomics market. On the other hand, the requirement of high capital investments and data management issues are expected to restrain the growth of this market to a certain extent.

Based on product, the reagents/consumables segment holds the largest market share during the forecast period.
Based on product & service, the RNA analysis/Transcriptomics market is segmented into reagents/consumables, instruments, software, and services.The reagents/consumables segment accounted for the larger market share in 2019.

The increasing demand for high-quality reagents and the repeated use of media and reagents in transcriptome studies. Additionally, the growing R&D activities in the pharmaceutical industry, growing government investments in the field of life science research, and the increasing research being undertaken with integrated omics studies are contributing to the market for consumables.

Based on technology, the sequencing technologies segment is expected to register the highest CAGR during the forecast period.
Based on technology, the RNA analysis/transcriptomics market is segmented into microarrays, PCR, sequencing technologies (Sanger sequencing and NGS technologies), and RNAi (gene silencing).The sequencing technologies segment is expected to witness the highest growth during the forecast period.

RNA sequencing allows direct access to sequences of mRNA and is an equitable technology, which makes it more suitable for target identification and drug discovery applications.RNA sequencing also helps to overcome several issues associated with microarrays, such as bias and variation due to hybridization and labeling efficiencies.

Technological advancements in this segment are further set to drive market growth.

The drug discovery segment is expected to account for the largest share of the RNA analysis/transcriptomics market in 2019
The drug discovery segment accounted for the largest share of the market in 2019.This is attributed to the use of transcriptomics in drug discovery for target identification and validation, identification of efficacy and toxicity biomarkers from biological fluids, and investigation of drug action and toxicity mechanisms.

The growing need to study a large number of genes to gain a better understanding of gene-to-drug interactions is further expected to drive the use of transcriptomic technologies in drug discovery applications.

CROs end user segment is expected to grow at the highest CAGR in the RNA analysis/transcriptomics market during the forecast period
Based on end user, the RNA analysis/transcriptomics market is segmented into academic & research institutes, pharmaceutical & biotechnology companies, hospitals & diagnostic centers, and contract research organizations.The contract research organizations (CROs) segment is expected to witness the highest growth during the forecast period.

CROs provide affordable outlets for companies and academia to pursue new medicines and offer a cost-effective solution to developing drugs.They also support foundations, research institutions, and universities, in addition to government organizations, such as the NIH and EMA.

These factors are driving the growth of this segment.

North America is expected to account for the largest share of the RNA analysis/transcriptomics market in 2019
In 2019, North America accounted for the largest share of the RNA analysis/transcriptomics market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa.The large share of this market segment can be attributed to the increasing development of structure-based drug designs, growing academic and government investments in genomics and proteomics research, high life science research funding, high biopharmaceutical R&D expenditure, and the greater adoption of advanced technologies in North America.

The presence of a large number of global players in this region is another key factor contributing to the large share of this market segment.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–35%, Tier 2–5%, and Tier 3–20%
• By Designation – C-level–35%, Director-level–25%, Others–40%
• By Region – North America–45%, Europe–30%, Asia Pacific–20%, Latin America- 3%, Middle East and Africa–2%

Key players in the RNA analysis/transcriptomics market
The key players operating in the RNA analysis/transcriptomics market include Thermo Fisher Scientific, Inc. (US), Bio-Rad Laboratories, Inc. (US), Merck KGaA (Germany), Agilent Technologies, Inc. (US), Illumina, Inc. (US), QIAGEN N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Danaher Corporation (US), Fluidigm Corporation (US), Eurofins Scientific (Germany), Sequentia Biotech SL (Spain), Acobiom (France), GenXPro GmbH (Germany), CD Genomics (US), Promega Corporation (US), Lexogen GmbH (Austria), Cenix BioScience GmbH (Germany), Takara Holdings, Inc. (Japan), bioMérieux SA (France), and LC Sciences LLC (US).

Research Coverage:
The report analyzes the RNA analysis/transcriptomics market and aims at estimating the market size and future growth potential of this market based on various segments such as product, technology, application, end user, and region.The report also includes a product portfolio matrix of various RNA analysis/transcriptomics products available in the market.

The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global RNA analysis/transcriptomics market. The report analyzes this market by product, technology, application, and end user
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global RNA analysis/transcriptomics market
• Market Development: Comprehensive information on the lucrative emerging markets by product, technology, application, and end user
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global RNA analysis/transcriptomics market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global RNA analysis/transcriptomics market.

Read the full report: https://www.reportlinker.com/p05983737/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001